Duality Advisers’s Biogen BIIB Stock Holding History

Duality Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,981	Closed	-$1.29M	–	66
2024 Q1	$1.29M	Buy	+5,981	New	+$1.4M	0.13%	264
2022 Q3	–	Sell	-23,848	Closed	-$4.86M	–	543
2022 Q2	$4.86M	Buy	23,848 +5,456	+30%	+$1.12M	0.48%	24
2022 Q1	$3.87M	Buy	+18,392	New	+$4M	0.42%	50

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Duality Advisers's BIIB Position: Q2 2024 in Review

Duality Advisers sold out of Biogen (BIIB) in Q2 2024, closing a stake of 5,981 shares — an estimated $1.29M sold.

Duality Advisers first reported a position in BIIB in Q1 2022 and held it in 3 quarters. The position peaked at $4.86M in Q2 2022. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Duality Advisers reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Duality Advisers sold 5,981 Biogen shares in Q2 2024, an estimated $1.29M.
Duality Advisers first reported a position in Biogen in Q1 2022 and held it in 3 quarters.
Duality Advisers's Biogen position peaked at $4.86M in Q2 2022.
943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.